[Skip to Content]
[Skip to Content Landing]
July 11, 1980

Hyperaldosteronism Associated With Liver Metastases

Author Affiliations

From the Departments of Human Oncology and Medicine (Drs Pandya, Whitehead, and Citrin) and Statistics (Dr Crowley), Wisconsin Clinical Cancer Center, University of Wisconsin, Madison. Dr Pandya is now with the Department of MedicineOncology, University of Rochester (NY) School of Medicine and Dentistry. Dr Citrin is a junior faculty fellow of the American Cancer Society.

JAMA. 1980;244(2):171-172. doi:10.1001/jama.1980.03310020047028

Plasma aldosterone levels were measured in 50 patients with confirmed liver metastases from various histologically proved primary tumors. None of these patients had electrolyte abnormalities or history of benign liver disease, congestive heart failure, hypertension, or renal disease. Patients with edema, ascites, or both had significantly greater elevation of plasma aldosterone levels compared to nonedematous patients; these patients also demonstrated a substantial degree of hepatic dysfunction as evidenced by lower serum albumin levels and higher bilirubin and alkaline phosphatase levels. This study provides a rational basis for the use of the specific aldosterone inhibitor spironolactone in the treatment of patients with advanced metastatic liver disease and edematous states.

(JAMA 244:171-172, 1980)